Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT00754650
A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 286
- Registration Number
- NCT00754559
A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 418
- Registration Number
- NCT00754572
A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.
Phase 3
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1072
- Registration Number
- NCT00755287
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
Phase 3
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: Placebo (matching sitagliptin)Drug: Placebo (matching taspoglutide)
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 666
- Registration Number
- NCT00754988
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1681
- Registration Number
- NCT00750880
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 373
- Registration Number
- NCT00744926
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
Phase 3
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT00744367
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Phase 2
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT00738374
- Locations
- 🇮🇹
Ospedale Cardarelli; Divisione Di Ematologia, Napoli, Campania, Italy
🇮🇹A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy
🇮🇹Arcispedale S. Anna; Sezione Di Ematologia, Ferrara, Emilia-Romagna, Italy
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Phase 3
Completed
- Conditions
- Renal Cell Cancer
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 649
- Registration Number
- NCT00738530
© Copyright 2025. All Rights Reserved by MedPath